Anna Sicuranza

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Immune Response

Chronic Myeloid Leukemia

Top Venues

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Elisabetta Abruzzese, Monica Bocchia, Malgorzata Monika Trawinska, Donatella Raspadori, Francesco Bondanini, Anna Sicuranza, Paola Pacelli, Federica Re, Alessia Cavalleri, Mirko Farina, Michele Malagola, Domenico Russo, Paolo De Fabritiis, Simona Bernardi
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR). Cancers 15 (16) (2023)
Emanuele Cencini, Anna Sicuranza, Sara Ciofini, Alberto Fabbri, Monica Bocchia, Alessandro Gozzetti
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications. Current oncology (Toronto, Ont.) 30 (7) (2023)
Adele Santoni, Margherita Malchiodi, Elisabetta Zappone, Anna Sicuranza, Monica Bocchia
Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis. Leukemia (2023)
Anna Sicuranza, Donatella Raspadori, Monica Bocchia
CD26/DPP-4 in Chronic Myeloid Leukemia. Cancers 14 (4) (2022)
Claudia Gandolfo, Gabriele Anichini, Marco Mugnaini, Monica Bocchia, Chiara Terrosi, Anna Sicuranza, Gianni Gori Savellini, Alessandro Gozzetti, Federico Franchi, Maria Grazia Cusi
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine. Vaccines 10 (2) (2022)
Fabio Fiorino, Anna Sicuranza, Annalisa Ciabattini, Adele Santoni, Gabiria Pastore, Martina Simoncelli, Jacopo Polvere, Sara Galimberti, Stefano Auddino, Claudia Baratè, Francesca Montagnani, Vincenzo Sammartano, Monica Bocchia, Donata Medaglini
The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. Biomedicines 9 (10) (2021)